Glaukos Co. (NYSE:GKOS) Stock Holdings Boosted by GAMMA Investing LLC

GAMMA Investing LLC grew its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 5,912.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 133,064 shares of the medical instruments supplier's stock after buying an additional 130,851 shares during the period. GAMMA Investing LLC owned 0.24% of Glaukos worth $13,096,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GKOS. Empowered Funds LLC purchased a new stake in shares of Glaukos during the 4th quarter valued at about $236,000. Louisiana State Employees Retirement System grew its position in Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock valued at $4,003,000 after acquiring an additional 100 shares in the last quarter. Legato Capital Management LLC raised its stake in shares of Glaukos by 85.0% during the fourth quarter. Legato Capital Management LLC now owns 9,381 shares of the medical instruments supplier's stock valued at $1,407,000 after purchasing an additional 4,309 shares during the period. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter valued at approximately $90,000. Finally, Rhumbline Advisers lifted its position in shares of Glaukos by 0.3% during the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock worth $21,260,000 after purchasing an additional 403 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GKOS shares. Mizuho dropped their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Stephens cut their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley reduced their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their price target on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Stock Performance

Glaukos stock traded up $1.04 during mid-day trading on Tuesday, reaching $95.68. The company's stock had a trading volume of 778,321 shares, compared to its average volume of 716,348. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The business has a 50 day moving average price of $91.90 and a 200-day moving average price of $120.74. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of -33.34 and a beta of 0.80.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company's quarterly revenue was up 24.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.70) EPS. Sell-side analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.80% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.